Retour

RaySearch Laboratories AB (publ)

Qualité des données : 100%

Survendu

RSLBF

OTC Healthcare Medical - Healthcare Information Services

23,00 €

0,00 € (0,00%)

Cap. Boursière : 822,17M

Fourchette du Jour

23,00 € 23,00 €

Fourchette 52 Semaines

20,60 € 37,36 €

Volume

Moyenne 50J / 200J

25,46 € / 28,72 €

Clôture Précédente

23,00 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique	Action	Médiane du Secteur
P/E	3,6	0,4
P/B	0,8	2,9
ROE %	24,5	3,7
Net Margin %	17,0	3,8
Rev Growth 5Y %	20,3	10,0
D/E	0,4	0,2

Points Clés

Revenue grew 20,31% annually over 5 years — strong growth

ROE of 24,47% indicates high profitability

Net margin of 16,95% shows strong profitability

Debt/Equity of 0,40 — conservative balance sheet

Generating 158,90M in free cash flow

P/E of 3,61 — trading at a low valuation

Croissance

Revenue Growth (5Y)

20,31%

Revenue (1Y)12,77%

Earnings (1Y)11,93%

FCF Growth (3Y)-19,73%

Qualité

Return on Equity

24,47%

ROIC15,88%

Net Margin16,95%

Op. Margin21,74%

Sécurité

Debt / Equity

0,40

Current Ratio1,70

Interest Coverage0,00

Valorisation

P/E Ratio

3,61

P/B Ratio0,83

EV/EBITDA2,77

Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	12,77%	Revenue Growth (3Y)	14,68%
Earnings Growth (1Y)	11,93%	Earnings Growth (3Y)	67,11%
Revenue Growth (5Y)	20,31%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	1,34B	Net Income (TTM)	227,80M
ROE	24,47%	ROA	11,44%
Gross Margin	92,42%	Operating Margin	21,74%
Net Margin	16,95%	Free Cash Flow (TTM)	158,90M
ROIC	15,88%	FCF Growth (3Y)	-19,73%
Safety
Debt / Equity	0,40	Current Ratio	1,70
Interest Coverage	0,00	Dividend Yield	0,01%
Valuation
P/E Ratio	3,61	P/B Ratio	0,83
P/S Ratio	0,61	PEG Ratio	2,76
EV/EBITDA	2,77	Dividend Yield	0,01%
Market Cap	822,17M	Enterprise Value	809,67M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1,34B	1,19B	1,02B	843,65M	641,67M
Net Income	227,80M	203,51M	81,57M	23,78M	-47,32M
EPS (Diluted)	6,65	5,94	2,38	0,69	-1,38
Gross Profit	1,24B	1,09B	915,58M	748,66M	591,28M
Operating Income	292,30M	260,49M	114,88M	42,74M	-52,64M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	1,99B	2,09B	1,95B	1,88B	1,74B
Total Liabilities	1,01B	1,21B	1,22B	1,22B	1,12B
Shareholders' Equity	985,30M	876,71M	735,23M	657,16M	628,31M
Total Debt	394,80M	471,93M	529,36M	555,39M	561,40M
Cash & Equivalents	407,30M	462,74M	343,68M	160,27M	102,54M
Current Assets	970,70M	984,75M	802,45M	627,92M	516,37M
Current Liabilities	569,90M	703,82M	675,05M	614,10M	490,08M

Scores de Stratégies

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Deep Value Investing (Seth Klarman)

#673 of 820

Growth Price/Sales Ratio Focus (Ken Fisher)

#237 of 616

Custom Contrarian Investing (David Dreman)

#218 of 658

Value Defensive Investing (Benjamin Graham)

#144 of 708

Value Value Investing (Warren Buffett)

#132 of 195

Activité Récente

Entré Deep Value Investing (Seth Klarman)

Mar 24, 2026

Entré Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Entré Contrarian Investing (David Dreman)

Mar 24, 2026

Entré Defensive Investing (Benjamin Graham)

Mar 24, 2026

Entré Value Investing (Warren Buffett)

Mar 24, 2026